CHU De Bordeauxt — Clinical Trial Site

35 Registered trials

10 Currently recruiting

Organisation

CHU De Bordeauxt

Location

Bordeaux Cedex, France

Identifier

ORG-100029701

Address

1 Rue Jean Burguet, Cs 11261, 33075, France

Departments

#98325007: Dermatologie
1804; Internal medecine and infectious diseases
33
Département d'oncologie médicale
Dermatologie
Dermatology
Hepato-Gastroenterology and Digestive Oncology
hepatogastroenterologie
Hopital Saint-Andre, Département d'oncologie médicale
Internal medicine
médecine nucléaire
Medical Oncology department
N/A
Oncologie Médicale
Oncology department
pediatric hematology and oncology
Pediatric Nephrology Unit
PNEUMOLOGY
Service d'Oncologie
Service d'Oncologie Médicale
Service d’Oncologie Médicale
Service de Dermatologie
Service Dermatologie et Dermatologie Pédiatrique
Service Oncologie Médicale
Unite de Dermatologie

Clinical trials at this site (35)

Search interface

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients Pending

2024-514144-85-02 Glioblastoma 3
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimeta… Recruiting

2023-503322-39-00 Newly diagnosed patients with metastatic (other than lu 3 2023-06-16
A Phase III study to evaluate the efficacy of INM004 (Shiga antitoxin) in pediatric patients with Shiga toxin-producing Escherichia coli-ass… Recruiting

2024-512412-22-00 Hemolytic Uremic Syndrome 5 2025-06-24
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re… Recruiting

2022-502972-22-00 Clostridioides difficile infection. 5 2024-10-31
OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Stud… Recruiting

2022-501408-81-01 Covid-19 4 2024-03-04
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting

2023-503661-28-00 Hidradenitis Suppurativa 5 2023-10-26
VAC-WARTS Recruiting

2024-513671-40-00 HPV vaccine 5 2022-06-29
HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate im… Recruiting

2024-516104-42-00 hematologic malignancies ; acute myeloid leukemias 1 2022-02-17
Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine ad… Recruiting

2024-514603-34-00 intermediate-risk differentiated thyroid cancer patient 5 2020-03-02
A phase I/II trial of TG4050, an individualised gene therapy, in patients with advanced cancer of the head and neck. Recruiting

2023-508561-33-00 Newly diagnosed, stage III or IV amenable to surgery, H 7 2019-12-12
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Hidradenitis Suppurativa 5 2024-07-26
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mut… Ended

2024-511548-19-00 Pancreatic Ductal Adenocarcinoma 1 2022-12-13
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended

2023-503999-24-00 Patients With Locally Advanced (Stage III), Unresectabl 5 2022-06-01
A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for locally advanced/metastatic Non-S… Ended

2023-503674-20-00 Unresectable, locally advanced, or metastatic Non-Small 5 2021-12-17
A Phase 2 Clinical Study to Assess the Safety and Efficacy of Deucravacitinib in Participants with Active DLE and/or SCLE Ended

2023-504161-22-00 Active Discoid and/or Subacute Cutaneous Lupus Erythema 4 2021-06-04
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended

2023-504959-27-00 Participants with Limited Stage-Small Cell Lung Cancer, 5 2020-12-09
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto… Ended

2023-504932-16-00 Muscle Invasive Bladder Cancer 5 2019-06-04
EffisayilTM ON: A study to test long-term treatment with spesolimab in people with generalized pustular psoriasis who took part in a previou… Ended

2023-509216-28-00 Generalized Pustular Psoriasis 4 2019-05-27
TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT… Ended

2023-509087-20-00 Metastatic Castration-resistant Prostate Cancer 5 2019-04-16
A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended

2023-506558-20-00 Dermatitis atopic 5 2024-06-26
A clinical study of MK-6194 for the treatment of vitiligo (MK-6194-007) Ended

2023-503502-37-00 Non segmental vitiligo 4 2024-01-24
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended

2022-502476-23-00 Treatment of immunotherapy-naive patients with previous 4 2023-10-25